Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark.

Abstract

AIMS:

To determine whether beta-blockers, aspirin, and statins are underutilized after first-time myocardial infarction (MI) in patients with chronic obstructive pulmonary disease (COPD) compared with patients without COPD. Further, to determine temporal trends and risk factors for non-use.

METHODS AND RESULTS:

Using Danish nationwide registers, we performed a cross-sectional study investigating the utilization of beta-blockers, aspirin, and statins after hospitalization for first-time MI among patients with and without COPD from 1995 to 2015. Risk factors for non-use were examined in multivariable logistic regression models. During 21 years of study, 140 278 patients were included, hereof 13 496 (9.6%) with COPD. Patients with COPD were less likely to use beta-blockers (53.2% vs. 76.2%, P < 0.001), aspirin (73.9% vs. 78.8%, P < 0.001), and statins (53.5% vs. 61.9%, P < 0.001). Medication usage increased during the study period but in multivariable analyses, COPD remained a significant predictor for non-use: odds ratio (95% confidence interval) for non-use of beta-blockers 1.86 (1.76-1.97); aspirin 1.24 (1.16-1.32); statins 1.50 (1.41-1.59). Analyses stratified by ST-segment elevation myocardial infarction (STEMI) and non-STEMI showed similar undertreatment of COPD patients. Risk factors for non-use of beta-blockers in COPD included increasing age, female sex, and increasing severity of COPD (frequent exacerbations, use of multiple inhaled medications, and low lung function). Similar findings were demonstrated for aspirin and statins.

CONCLUSION:

Beta-blockers, and to a lesser extent aspirin and statins, were systematically underutilized by patients with COPD following hospitalization for MI despite an overall increase in the utilization over time. Increasing severity of COPD was a risk factor for non-use of the medications.

• Authors: Daniel Bech Rasmussen, Uffe Bodtger, Morten Lamberts, Sia Kromann Nicolaisen, Maurizio Sessa, Annalisa Capuano, Christian Torp-Pedersen, Gunnar Gislason, Peter Lange, Magnus Thorsten Jensen
• Journal: European heart journal. Quality of care & clinical outcomes (Eur Heart J Qual Care Clin Outcomes) Vol. 6 Issue 1 Pg. 23-31 (01 01 2020) ISSN: 2058-1742 [Electronic] England
• PMID: 30608575 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: [email protected].

Chemical References

• Adrenergic beta-Antagonists
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Aspirin

Topics

• Adrenergic beta-Antagonists (therapeutic use)
• Aged
• Aged, 80 and over
• Aspirin (therapeutic use)
• Cross-Sectional Studies
• Denmark (epidemiology)
• Drug Therapy, Combination
• Female
• Hospitalization
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Incidence
• Male
• Middle Aged
• Myocardial Infarction (complications, drug therapy, epidemiology)
• Population Surveillance
• Pulmonary Disease, Chronic Obstructive (complications, drug therapy, epidemiology)
• Registries
• Risk Factors
• Survival Rate (trends)